.Pharmacolibrary.Drugs.ATC.D.D11AH05

Information

Dupilumab is a fully human monoclonal antibody that inhibits signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13) by binding to the IL-4 receptor alpha subunit. It is used in the treatment of moderate-to-severe atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis, and is an FDA and EMA approved biologic drug.

Pharmacokinetics

Pharmacokinetics reported from adult patients with atopic dermatitis; population PK analyses evaluated after subcutaneous administration in healthy or affected subjects.

References

1. Kamal, MA, et al., & Arima, K (2022). Pharmacokinetics, pharmacodynamics, and exposure-efficacy of dupilumab in adults with atopic dermatitis. Clinical and translational science 15(10) 2342–2354. DOI:10.1111/cts.13363 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35986664

2. Cork, MJ, et al., & Levit, NA (2023). Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6-11 Years of Age with Severe Atopic Dermatitis. Dermatology and therapy 13(11) 2697–2719. DOI:10.1007/s13555-023-01016-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37750994

3. Zhang, L, et al., & Lu, Q (2021). Population pharmacokinetic analysis of dupilumab in adult and adolescent patients with asthma. CPT: pharmacometrics & systems pharmacology 10(8) 941–952. DOI:10.1002/psp4.12667 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34313019

Revisions

• 06/2025 initial generated model